Novel HDAC6 inhibitor, ricolinostat, for the treatment of multiple myeloma

Noopur Raje

At the Myeloma 2015 meeting, Dr Noopur Raje (Massachusetts General Hospital, Boston, MA) discusses the clinical development of the selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat, for the treatment of multiple myeloma. Clinical results to date suggest that ricolinostat is likely to operate synergistically with other agents.

Share this video  
Multiple Myeloma
Myeloma 2015
11th April 2015
More from Noopur Raje
Results of Phase III POLLUX trial on daratumumab in multiple myeloma
Results of Phase Ib/II study of ricolinostat in multiple myeloma
Myeloma 2016: Panel discussion on in vivo drug screening
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals